NeuroSense Therapeutics Ltd. (NRSN)
Chart Events
Performance Outlook
| Previous Close | 0.7000 |
| Open | 0.7800 |
| Bid | 0.7200 x 3200 |
| Ask | 0.7600 x 900 |
| Day's Range | 0.7542 - 0.7800 |
| 52 Week Range | 0.7000 - 2.9100 |
| Volume | |
| Avg. Volume | 38,012 |
| Market Cap | 10.353M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NRSN
Related Research
- NeuroSense Therapeutics Ltd.Daily – Vickers Top Insider Picks for 09/28/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat7 hours agoArgus Research
- PR Newswire
European Medicines Agency Grants NeuroSense SME Status
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that it has opened an EU Office as well as been granted the Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval. The EMA already granted PrimeC Orphan Drug Status for the treatment of ALS.
- PR Newswire
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that the European, Japan, and Israel Patent Offices have granted the Company a key patent relating to "Compositions comprising an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases." The patents relate to NeuroSense's unique fixed-dose combination of ciprofloxacin and celecoxib, two U.S. Food and Drug Administration
- PR Newswire
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today it will participate in the following ALS conferences.
